Figure 3.

CD271-responsive genes are predominantly expressed in chemoresistant cells. (a) GSEA with profiling data of MeWo^Fote, MeWo^Vind and MeWo^Eto cells and a consensus signature, comprising 516 CD271-responsive genes. FDR, false discovery rate; NES, nominal enrichment score; NS, no significant enrichment. (b) Venn diagram depicting commonly found CD271-responsive genes in chemoresistant cells. FGF13 represents the most common gene in MeWo^Fote and MeWo^Vind cells. (c) Left panel: qPCR of MeWo^Fote and MeWo^Par cells and right panel: MeWo^Fote cells stably transfected with a validated CD271-targeting shRNA (shCD271) or control (shCtl.) for expression of CD271 and FGF13. (d) Immunoblot analysis of whole-cell lysates of MeWo^Par cells either non-transfected (Mock) or engineered to stably express CD271 (NGFR, GFP-tagged) for levels of CD271. (e) Expression level of FGF13 in MeWo^Par cells either stably or transiently expressing CD271. (f) Determination of viability of MeWo^Cis (Cis) and MeWo^Fote (Fote) cells as compared with stably GFP (Par-GFP) or NGFR/CD271-expressing MeWo^Par (Par-NGFR) cells following a dose-dependent treatment with either cisplatin (μM) or fotemustine (μg/ml). Viability is indicated in %±s.d. of n=8 technical replicates. A representative out of n=3 biological replicates is shown.